<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33486755</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5381</ISSN><JournalIssue CitedMedium="Internet"><Volume>178</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>British journal of pharmacology</Title><ISOAbbreviation>Br J Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Targeting the CB<sub>2</sub> receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>1373</StartPage><EndPage>1387</EndPage><MedlinePgn>1373-1387</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bph.15386</ELocationID><Abstract><AbstractText>Cannabinoids form a singular group of plant-derived compounds, endogenous lipids and synthetic derivatives with multiple therapeutic effects exerted by targeting different elements of the endocannabinoid system. One of their therapeutic applications is the preservation of neuronal integrity exerted by attenuating the multiple neurotoxic events that kill neurons in neurodegenerative disorders. In this review, we will address the potential of cannabinoids as neuroprotective agents in amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disorder characterized by muscle denervation, atrophy and paralysis, and progressive deterioration in upper and/or lower motor neurons. The emphasis will be paid on the cannabinoid type 2 (CB<sub>2</sub> ) receptor, whose activation limits glial reactivity, but the potential of additional endocannabinoid-related targets will be also addressed. The evidence accumulated so far at the preclinical level supports the need to soon move towards the patients and initiate clinical trials to confirm the potential of cannabinoid-based medicines as disease modifiers in ALS. LINKED ARTICLES: This article is part of a themed issue on Neurochemistry in Japan. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.6/issuetoc.</AbstractText><CopyrightInformation>&#xa9; 2021 The British Pharmacological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Cueto</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-3891-4049</Identifier><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED, Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Area 1 - Neurociencias y Organos de los Sentidos, IRYCIS, Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Toscano</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED, Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Area 1 - Neurociencias y Organos de los Sentidos, IRYCIS, Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santos-Garc&#xed;a</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED, Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Area 1 - Neurociencias y Organos de los Sentidos, IRYCIS, Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Almer&#xed;a</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED, Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Area 1 - Neurociencias y Organos de los Sentidos, IRYCIS, Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalo-Consuegra</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED, Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Area 1 - Neurociencias y Organos de los Sentidos, IRYCIS, Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espejo-Porras</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED, Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Area 1 - Neurociencias y Organos de los Sentidos, IRYCIS, Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Ruiz</LastName><ForeName>Javier</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4490-0604</Identifier><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED, Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Area 1 - Neurociencias y Organos de los Sentidos, IRYCIS, Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Lago</LastName><ForeName>Eva</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-6260-3777</Identifier><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED, Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Area 1 - Neurociencias y Organos de los Sentidos, IRYCIS, Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ELA-Madrid (B2017/BMD-3813)</GrantID><Agency>Comunidad de Madrid</Agency><Country/></Grant><Grant><GrantID>CB06/05/0089</GrantID><Agency>CIBERNED, Instituto de Salud Carlos III</Agency><Country/></Grant><Grant><GrantID>RTI2018-098885-B-100</GrantID><Agency>Ministerio de Ciencia e Innovaci&#xf3;n</Agency><Country/></Grant><Grant><Agency>GW Pharmaceuticals</Agency><Country/></Grant><Grant><Agency>Emerald Health Pharmaceuticals</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Pharmacol</MedlineTA><NlmUniqueID>7502536</NlmUniqueID><ISSNLinking>0007-1188</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002186">Cannabinoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D063388">Endocannabinoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043884">Receptor, Cannabinoid, CB1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043885">Receptor, Cannabinoid, CB2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002186" MajorTopicYN="Y">Cannabinoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063388" MajorTopicYN="N">Endocannabinoids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043884" MajorTopicYN="N">Receptor, Cannabinoid, CB1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043885" MajorTopicYN="N">Receptor, Cannabinoid, CB2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CB2 receptors</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">cannabinoids</Keyword><Keyword MajorTopicYN="N">endocannabinoid signalling system</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">neuroprotection</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>24</Day><Hour>20</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33486755</ArticleId><ArticleId IdType="doi">10.1111/bph.15386</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Al-Chalabi, A., &amp; Hardiman, O. (2013). The epidemiology of ALS: A conspiracy of genes, environment and time. Nature Reviews. Neurology, 9, 617-628. https://doi.org/10.1038/nrneurol.2013.203</Citation></Reference><Reference><Citation>Alexander, S. P. H., Christopoulos, A., Davenport, A. P., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., &amp; Pawson, A. J. (2019). The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology, 176(Suppl 1), S21-S141.</Citation></Reference><Reference><Citation>Alexander, S. P. H., Cidlowski, J. A., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., &amp; Sharman, J. L. (2019). The Concise Guide to PHARMACOLOGY 2019/20: Nuclear hormone receptors. British Journal of Pharmacology, 176(Suppl 1), S229-S246.</Citation></Reference><Reference><Citation>Alexander, S. P. H., Fabbro, D., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., &amp; Sharman, J. L. (2019). The Concise Guide to PHARMACOLOGY 2019/20: Enzymes. British Journal of Pharmacology, 176(Suppl 1), S297-S396.</Citation></Reference><Reference><Citation>Alexander, S. P. H., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., &amp; Southan, C. (2019). The Concise Guide to PHARMACOLOGY 2019/20: Introduction and other protein targets. British Journal of Pharmacology, 176(Suppl 1), S1-S20.</Citation></Reference><Reference><Citation>Amtmann, D., Weydt, P., Johnson, K. L., Jensen, M. P., &amp; Carter, G. T. (2004). Survey of cannabis use in patients with amyotrophic lateral sclerosis. The American Journal of Hospice &amp; Palliative Care, 21, 95-104. https://doi.org/10.1177/104990910402100206</Citation></Reference><Reference><Citation>Arevalo-Martin, A., Molina-Holgado, E., &amp; Garcia-Ovejero, D. (2016). Cannabinoids to treat spinal cord injury. Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry, 64, 190-199. https://doi.org/10.1016/j.pnpbp.2015.03.008</Citation></Reference><Reference><Citation>Atalay, S., Jarocka-Karpowicz, I., &amp; Skrzydlewska, E. (2019). Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants (Basel), 9, 21. https://doi.org/10.3390/antiox9010021</Citation></Reference><Reference><Citation>Atwood, B. K., &amp; Mackie, K. (2010). CB2: A cannabinoid receptor with an identity crisis. British Journal of Pharmacology, 160, 467-479. https://doi.org/10.1111/j.1476-5381.2010.00729.x</Citation></Reference><Reference><Citation>Aymerich, M. S., Aso, E., Abellanas, M. A., Tolon, R. M., Ramos, J. A., Ferrer, I., Romero, J., &amp; Fern&#xe1;ndez-Ruiz, J. (2018). Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system. Biochemical Pharmacology, 157, 67-84. https://doi.org/10.1016/j.bcp.2018.08.016</Citation></Reference><Reference><Citation>Bhandari, R., Kuhad, A., &amp; Kuhad, A. (2018). Edaravone: A new hope for deadly amyotrophic lateral sclerosis. Drugs of Today (Barcelona, Spain: 1998), 54, 349-360. https://doi.org/10.1358/dot.2018.54.6.2828189</Citation></Reference><Reference><Citation>Bilsland, L. G., Dick, J. R., Pryce, G., Petrosino, S., Di Marzo, V., Baker, D., Greensmith, L., Bilsland, L. G., Dick, J. R., Pryce, G., &amp; Petrosino, S. (2006). Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. The FASEB Journal, 20, 1003-1005. https://doi.org/10.1096/fj.05-4743fje</Citation></Reference><Reference><Citation>Bilsland, L. G., &amp; Greensmith, L. (2008). The endocannabinoid system in amyotrophic lateral sclerosis. Current Pharmaceutical Design, 14, 2306-2316. https://doi.org/10.2174/138161208785740081</Citation></Reference><Reference><Citation>Butti, Z., &amp; Patten, S. A. (2019). RNA dysregulation in amyotrophic lateral sclerosis. Frontiers in Genetics, 9, 712. https://doi.org/10.3389/fgene.2018.00712</Citation></Reference><Reference><Citation>Calignano, A., La Rana, G., Giuffrida, A., &amp; Piomelli, D. (1998). Control of pain initiation by endogenous cannabinoids. Nature, 394, 277-281. https://doi.org/10.1038/28393</Citation></Reference><Reference><Citation>Carter, G. T., Abood, M. E., Aggarwal, S. K., &amp; Weiss, M. D. (2010). Cannabis and amyotrophic lateral sclerosis: Hypothetical and practical applications, and a call for clinical trials. The American Journal of Hospice &amp; Palliative Care, 27, 347-356. https://doi.org/10.1177/1049909110369531</Citation></Reference><Reference><Citation>Cheah, B. C., Vucic, S., Krishnan, A. V., &amp; Kiernan, M. C. (2010). Riluzole, neuroprotection and amyotrophic lateral sclerosis. Current Medicinal Chemistry, 17, 1942-1949. https://doi.org/10.2174/092986710791163939</Citation></Reference><Reference><Citation>Chi&#xf2;, A., Mora, G., &amp; Lauria, G. (2017). Pain in amyotrophic lateral sclerosis. Lancet Neurology, 16, 144-157. https://doi.org/10.1016/S1474-4422(16)30358-1</Citation></Reference><Reference><Citation>Clemente, S. (2012). Amyotrophic lateral sclerosis treatment with ultramicronized palmitoylethanolamide: A case report. CNS &amp; Neurological Disorders Drug Targets, 11, 933-936. https://doi.org/10.2174/1871527311201070933</Citation></Reference><Reference><Citation>Costa, L., Amaral, C., Teixeira, N., Correia-da-Silva, G., &amp; Fonseca, B. M. (2016). Cannabinoid-induced autophagy: Protective or death role? Prostaglandins &amp; Other Lipid Mediators, 122, 54-63. https://doi.org/10.1016/j.prostaglandins.2015.12.006</Citation></Reference><Reference><Citation>Cristino, L., Bisogno, T., &amp; Di Marzo, V. (2020). Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nature Reviews. Neurology, 16, 9-29. https://doi.org/10.1038/s41582-019-0284-z</Citation></Reference><Reference><Citation>Das, S., Kaul, K., Mishra, S., Charan, M., &amp; Ganju, R. K. (2019). Cannabinoid signaling in cancer. Advances in Experimental Medicine and Biology, 1162, 51-61. https://doi.org/10.1007/978-3-030-21737-2_4</Citation></Reference><Reference><Citation>De Lago, E., Moreno-Martet, M., Espejo-Porras, F., &amp; Fern&#xe1;ndez-Ruiz, J. (2015). Endocannabinoids and amyotrophic lateral sclerosis. In L. Fattore (Ed.), Cannabinoids in neurological and mental disorders (pp. 99-124). Amsterdam: Elsevier.</Citation></Reference><Reference><Citation>Espejo-Porras, F., Fern&#xe1;ndez-Ruiz, J., &amp; de Lago, E. (2018). Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener, 19, 377-386. https://doi.org/10.1080/21678421.2018.1425454</Citation></Reference><Reference><Citation>Espejo-Porras, F., Garc&#xed;a-Toscano, L., Rodr&#xed;guez-Cueto, C., Santos-Garc&#xed;a, I., de Lago, E., &amp; Fernandez-Ruiz, J. (2019). Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis. British Journal of Pharmacology, 176, 1585-1600. https://doi.org/10.1111/bph.14216</Citation></Reference><Reference><Citation>Espejo-Porras, F., Piscitelli, F., Verde, R., Ramos, J. A., Di Marzo, V., de Lago, E., &amp; Fern&#xe1;ndez-Ruiz, J. (2015). Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: Relevance for a neuroprotective therapy in TDP-43-related disorders. Journal of Neuroimmune Pharmacology, 10, 233-244. https://doi.org/10.1007/s11481-015-9602-4</Citation></Reference><Reference><Citation>Fern&#xe1;ndez-Ruiz, J. (2019). The biomedical challenge of neurodegenerative disorders: An opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomes. British Journal of Pharmacology, 176, 1370-1383. https://doi.org/10.1111/bph.14382</Citation></Reference><Reference><Citation>Fern&#xe1;ndez-Ruiz, J., Moro, M. A., &amp; Mart&#xed;nez-Orgado, J. (2015). Cannabinoids in neurodegenerative disorders and stroke/brain trauma: From preclinical models to clinical applications. Neurotherapeutics, 12, 793-806. https://doi.org/10.1007/s13311-015-0381-7</Citation></Reference><Reference><Citation>Fern&#xe1;ndez-Ruiz, J., Romero, J., Velasco, G., Tol&#xf3;n, R. M., Ramos, J. A., &amp; Guzm&#xe1;n, M. (2007). Cannabinoid CB2 receptor: A new target for controlling neural cell survival? Trends in Pharmacological Sciences, 28, 39-45. https://doi.org/10.1016/j.tips.2006.11.001</Citation></Reference><Reference><Citation>Fern&#xe1;ndez-Ruiz, J., Sagredo, O., Pazos, M. R., Garc&#xed;a, C., Pertwee, R., Mechoulam, R., &amp; Mart&#xed;nez-Orgado, J. (2013). Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid? British Journal of Clinical Pharmacology, 75, 323-333. https://doi.org/10.1111/j.1365-2125.2012.04341.x</Citation></Reference><Reference><Citation>Fern&#xe1;ndez-Trapero, M., Espejo-Porras, F., Rodr&#xed;guez-Cueto, C., Coates, J. R., P&#xe9;rez-D&#xed;az, C., de Lago, E., &amp; Fern&#xe1;ndez-Ruiz, J. (2017). Upregulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis. Disease Models &amp; Mechanisms, 10, 551-558. https://doi.org/10.1242/dmm.028373</Citation></Reference><Reference><Citation>Freitas, H. R., Isaac, A. R., Malcher-Lopes, R., Diaz, B. L., Trevenzoli, I. H., &amp; De Melo Reis, R. A. (2018). Polyunsaturated fatty acids and endocannabinoids in health and disease. Nutritional Neuroscience, 21, 695-714. https://doi.org/10.1080/1028415X.2017.1347373</Citation></Reference><Reference><Citation>Gao, F. B., Almeida, S., &amp; Lopez-Gonzalez, R. (2017). Dysregulated molecular pathways in amyotrophic lateral sclerosis-frontotemporal dementia spectrum disorder. The EMBO Journal, 36, 2931-2950. https://doi.org/10.15252/embj.201797568</Citation></Reference><Reference><Citation>Geevasinga, N., Menon, P., Ng, K., Van Den Bos, M., Byth, K., Kiernan, M. C., &amp; Vucic, S. (2016). Riluzole exerts transient modulating effects on cortical and axonal hyperexcitability in ALS. Amyotroph Lateral Scler Frontotemporal Degener, 17, 580-588. https://doi.org/10.1080/21678421.2016.1188961</Citation></Reference><Reference><Citation>Gelinas, D., Miller, R., &amp; Abood, M. (2002). A pilot study of safety and tolerability of &#x394;9-THC (marinol) treatment for ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 3, 23.</Citation></Reference><Reference><Citation>Giacoppo, S., &amp; Mazzon, E. (2016). Can cannabinoids be a potential therapeutic tool in amyotrophic lateral sclerosis? Neural Regeneration Research, 11, 1896-1899. https://doi.org/10.4103/1673-5374.197125</Citation></Reference><Reference><Citation>Gijselinck, I., Cruts, M., &amp; Van Broeckhoven, C. (2018). The genetics of C9orf72 expansions. Cold Spring Harbor Perspectives in Medicine, 8, a026757. https://doi.org/10.1101/cshperspect.a026757</Citation></Reference><Reference><Citation>Hardiman, O., van den Berg, L. H., &amp; Kiernan, M. C. (2011). Clinical diagnosis and management of amyotrophic lateral sclerosis. Nature Reviews. Neurology, 7, 639-649. https://doi.org/10.1038/nrneurol.2011.153</Citation></Reference><Reference><Citation>Haug, N. A., Kieschnick, D., Sottile, J. E., Babson, K. A., Vandrey, R., &amp; Bonn-Miller, M. O. (2016). Training and practices of cannabis dispensary staff. Cannabis and Cannabinoid Research, 1, 244-251. https://doi.org/10.1089/can.2016.0024</Citation></Reference><Reference><Citation>Husnain, M., Imran, M., Ibrahim, M., Assiri, M. A., Wattoo, N. Z., &amp; Irfan, A. (2020). Pharmacological analysis of Cannabis sativa: A potent herbal plant. Mini Reviews in Medicinal Chemistry. https://doi.org/10.2174/1389557520666200628031644 in press.</Citation></Reference><Reference><Citation>Izrael, M., Slutsky, S. G., &amp; Revel, M. (2020). Rising stars: Astrocytes as a therapeutic target for ALS disease. Frontiers in Neuroscience, 14, 824. https://doi.org/10.3389/fnins.2020.00824</Citation></Reference><Reference><Citation>Joerger, M., Wilkins, J., Fagagnini, S., Baldinger, R., Brenneisen, R., Schneider, U., Goldman, B., &amp; Weber, M. (2012). Single-dose pharmacokinetics and tolerability of oral delta-9-tetrahydrocannabinol in patients with amyotrophic lateral sclerosis. Drug Metabolism Letters, 6, 102-108. https://doi.org/10.2174/1872312811206020102</Citation></Reference><Reference><Citation>Joshi, N., &amp; Onaivi, E. S. (2019). Endocannabinoid system components: Overview and tissue distribution. Advances in Experimental Medicine and Biology, 1162, 1-12. https://doi.org/10.1007/978-3-030-21737-2_1</Citation></Reference><Reference><Citation>Kallendrusch, S., Kremzow, S., Nowicki, M., Grabiec, U., Winkelmann, R., Benz, A., Kraft, R., Bechmann, I., Dehghani, F., &amp; Koch, M. (2013). The G protein-coupled receptor 55 ligand l-&#x3b1;-lysophosphatidylinositol exerts microglia-dependent neuroprotection after excitotoxic lesion. Glia, 61, 1822-1831. https://doi.org/10.1002/glia.22560</Citation></Reference><Reference><Citation>Kaur, S. J., McKeown, S. R., &amp; Rashid, S. (2016). Mutant SOD1 mediated pathogenesis of amyotrophic lateral sclerosis. Gene, 577, 109-118. https://doi.org/10.1016/j.gene.2015.11.049</Citation></Reference><Reference><Citation>Kiaei, M., Kipiani, K., Chen, J., Calingasan, N. Y., &amp; Beal, M. F. (2005). Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Experimental Neurology, 191, 331-336. https://doi.org/10.1016/j.expneurol.2004.10.007</Citation></Reference><Reference><Citation>Kim, G., Gautier, O., Tassoni-Tsuchida, E., Ma, X. R., &amp; Gitler, A. D. (2020). ALS genetics: Gains, losses, and implications for future therapies. Neuron, 108(5), 822-842.</Citation></Reference><Reference><Citation>Kim, K., Moore, D. H., Makriyannis, A., &amp; Abood, M. E. (2006). AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. European Journal of Pharmacology, 542, 100-105. https://doi.org/10.1016/j.ejphar.2006.05.025</Citation></Reference><Reference><Citation>Kolb, B., Saber, H., Fadel, H., &amp; Rajah, G. (2019). The endocannabinoid system and stroke: A focused review. Brain Circulation, 5, 1-7. https://doi.org/10.4103/bc.bc_29_18</Citation></Reference><Reference><Citation>Lu, H. C., &amp; Mackie, K. (2020). Review of the endocannabinoid system. Biol Psychiatry Cogn Neurosci Neuroimaging. S2451-9022(20)30206-8</Citation></Reference><Reference><Citation>Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S. C., Cascio, M. G., Guti&#xe9;rrez, S. O., Van der Stelt, M., &amp; L&#xf3;pez-Rodr&#xed;guez, M. L. (2003). CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science, 302, 84-88. https://doi.org/10.1126/science.1088208</Citation></Reference><Reference><Citation>Mathew, B., Harilal, S., Musa, A., Kumar, R., Parambi, D. G. T., Jose, J., Uddin, M. S., Shah, M. A., Behl, T., &amp; Unnikrishnan, M. K. (2020). An Agathokakological tale of &#x2206;9-THC: Exploration of possible biological targets. Current Drug Targets. https://doi.org/10.2174/1389450121666201001123515 in press.</Citation></Reference><Reference><Citation>McDonald, T. S., McCombe, P. A., Woodruff, T. M., &amp; Lee, J. D. (2020). The potential interplay between energy metabolism and innate complement activation in amyotrophic lateral sclerosis. The FASEB Journal, 34, 7225-7233. https://doi.org/10.1096/fj.201901781</Citation></Reference><Reference><Citation>Moreno-Martet, M., Espejo-Porras, F., Fern&#xe1;ndez-Ruiz, J., &amp; de Lago, E. (2014). Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex&#xae;-like combination of phytocannabinoids: Interest for future therapies in amyotrophic lateral sclerosis. CNS Neuroscience &amp; Therapeutics, 20, 809-815. https://doi.org/10.1111/cns.12262</Citation></Reference><Reference><Citation>Ouali Alami, N., Schurr, C., Olde Heuvel, F., Tang, L., Li, Q., Tasdogan, A., Kimbara, A., Nettekoven, M., Ottaviani, G., Raposo, C., &amp; R&#xf6;ver, S. (2018). NF-&#x3ba;B activation in astrocytes drives a stage-specific beneficial neuroimmunological response in ALS. The EMBO Journal, 37, e98697.</Citation></Reference><Reference><Citation>Palma, E., Reyes-Ruiz, J. M., Lopergolo, D., Roseti, C., Bertollini, C., Ruffolo, G., Cifelli, P., Onesti, E., Limatola, C., Miledi, R., &amp; Inghilleri, M. (2016). Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy. Proceedings of the National Academy of Sciences of the United States of America, 113, 3060-3065. https://doi.org/10.1073/pnas.1600251113</Citation></Reference><Reference><Citation>Park, S. W., Yi, J. H., Miranpuri, G., Satriotomo, I., Bowen, K., Resnick, D. K., &amp; Vemuganti, R. (2007). Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. The Journal of Pharmacology and Experimental Therapeutics, 320, 1002-1012. https://doi.org/10.1124/jpet.106.113472</Citation></Reference><Reference><Citation>Pasquarelli, N., Engelskirchen, M., Hanselmann, J., Endres, S., Porazik, C., Bayer, H., Buck, E., Karsak, M., Weydt, P., Ferger, B., &amp; Witting, A. (2017). Evaluation of monoacylglycerol lipase as a therapeutic target in a transgenic mouse model of ALS. Neuropharmacology, 124, 157-169. https://doi.org/10.1016/j.neuropharm.2017.03.037</Citation></Reference><Reference><Citation>Petrosino, S., &amp; Di Marzo, V. (2017). The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. British Journal of Pharmacology, 174, 1349-1365. https://doi.org/10.1111/bph.13580</Citation></Reference><Reference><Citation>Petrov, D., Mansfield, C., Moussy, A., &amp; Hermine, O. (2017). ALS clinical trials review: 20&#x2009;years of failure. Are we any closer to registering a new treatment? Frontiers in Aging Neuroscience, 9, 68.</Citation></Reference><Reference><Citation>Pistis, M., &amp; O'Sullivan, S. E. (2017). The role of nuclear hormone receptors in cannabinoid function. Advances in Pharmacology, 80, 291-328. https://doi.org/10.1016/bs.apha.2017.03.008</Citation></Reference><Reference><Citation>Pryce, G., &amp; Baker, D. (2015). Endocannabinoids in multiple sclerosis and amyotrophic lateral sclerosis. Handbook of Experimental Pharmacology, 231, 213-231. https://doi.org/10.1007/978-3-319-20825-1_7</Citation></Reference><Reference><Citation>Raman, C., McAllister, S. D., Rizvi, G., Patel, S. G., Moore, D. H., &amp; Abood, M. E. (2004). Amyotrophic lateral sclerosis: Delayed disease progression in mice by treatment with a cannabinoid. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 5, 33-39. https://doi.org/10.1080/14660820310016813</Citation></Reference><Reference><Citation>Renton, A. E., Majounie, E., Waite, A., Sim&#xf3;n-S&#xe1;nchez, J., Rollinson, S., Gibbs, J. R., Schymick, J. C., Laaksovirta, H., Van Swieten, J. C., Myllykangas, L., &amp; Traynor, B. J. (2011). A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron, 72, 257-268. https://doi.org/10.1016/j.neuron.2011.09.010</Citation></Reference><Reference><Citation>Riva, N., Mora, G., Sorar&#xf9;, G., Lunetta, C., Ferraro, O. E., Falzone, Y., &#x2026; CANALS Study Group (2019). Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet Neurology, 18(2), 155-164. https://doi.org/10.1016/S1474-4422(18)30406-X</Citation></Reference><Reference><Citation>Rodr&#xed;guez-Cueto, C., Santos-Garc&#xed;a, I., Garc&#xed;a-Toscano, L., Espejo-Porras, F., Bellido, M., Fern&#xe1;ndez-Ruiz, J., Mu&#xf1;oz, E., &amp; de Lago, E. (2018). Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis. Biochemical Pharmacology, 157, 217-226. https://doi.org/10.1016/j.bcp.2018.07.049</Citation></Reference><Reference><Citation>Rossi, S., Bernardi, G., &amp; Centonze, D. (2010). The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis. Experimental Neurology, 224, 92-102. https://doi.org/10.1016/j.expneurol.2010.03.030</Citation></Reference><Reference><Citation>Rossi, S., De Chiara, V., Musella, A., Cozzolino, M., Bernardi, G., Maccarrone, M., Mercuri, N. B., Carr&#xec;, M. T., &amp; Centonze, D. (2010). Abnormal sensitivity of cannabinoid CB1 receptors in the striatum of mice with experimental amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis, 11, 83-90. https://doi.org/10.3109/17482960902977954</Citation></Reference><Reference><Citation>Sargsyan, S. A., Monk, P. N., &amp; Shaw, P. J. (2005). Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis. Glia, 51, 241-253. https://doi.org/10.1002/glia.20210</Citation></Reference><Reference><Citation>Sch&#xfc;tz, B., Reimann, J., Dumitrescu-Ozimek, L., Kappes-Horn, K., Landreth, G. E., Sch&#xfc;rmann, B., Zimmer, A., &amp; Heneka, M. T. (2005). The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. The Journal of Neuroscience, 25, 7805-7812. https://doi.org/10.1523/JNEUROSCI.2038-05.2005</Citation></Reference><Reference><Citation>Shoemaker, J. L., Seely, K. A., Reed, R. L., Crow, J. P., &amp; Prather, P. L. (2007). The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. Journal of Neurochemistry, 101, 87-98. https://doi.org/10.1111/j.1471-4159.2006.04346.x</Citation></Reference><Reference><Citation>Shohami, E., Cohen-Yeshurun, A., Magid, L., Algali, M., &amp; Mechoulam, R. (2011). Endocannabinoids and traumatic brain injury. British Journal of Pharmacology, 163, 1402-1410. https://doi.org/10.1111/j.1476-5381.2011.01343.x</Citation></Reference><Reference><Citation>Turner, M. R., Cagnin, A., Turkheimer, F. E., Miller, C. C., Shaw, C. E., Brooks, D. J., Leigh, P. N., &amp; Banati, R. B. (2004). Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: An [11C](R)-PK11195 positron emission tomography study. Neurobiology of Disease, 15, 601-609. https://doi.org/10.1016/j.nbd.2003.12.012</Citation></Reference><Reference><Citation>Urbi, B., Broadley, S., Bedlack, R., Russo, E., &amp; Sabet, A. (2019). Study protocol for a randomised, double-blind, placebo-controlled study evaluating the efficacy of cannabis-based medicine extract in slowing the disease progression of amyotrophic lateral sclerosis or motor neuron disease: The EMERALD trial. BMJ Open, 9, e029449. https://doi.org/10.1136/bmjopen-2019-029449</Citation></Reference><Reference><Citation>Van Damme, P., Robberecht, W., &amp; Van Den Bosch, L. (2017). Modelling amyotrophic lateral sclerosis: Progress and possibilities. Disease Models &amp; Mechanisms, 10, 537-549. https://doi.org/10.1242/dmm.029058</Citation></Reference><Reference><Citation>Weber, M., Goldman, B., &amp; Truniger, S. (2010). Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: A randomised, double-blind crossover trial. Journal of Neurology, Neurosurgery, and Psychiatry, 81, 1135-1140. https://doi.org/10.1136/jnnp.2009.200642</Citation></Reference><Reference><Citation>Weydt, P., Hong, S., Witting, A., M&#xf6;ller, T., Stella, N., &amp; Kliot, M. (2005). Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 6, 182-184. https://doi.org/10.1080/14660820510030149</Citation></Reference><Reference><Citation>Witting, A., Weydt, P., Hong, S., Kliot, M., Moller, T., &amp; Stella, N. (2004). Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice. Journal of Neurochemistry, 89, 1555-1557. https://doi.org/10.1111/j.1471-4159.2004.02544.x</Citation></Reference><Reference><Citation>Wright, S. (2007). Cannabinoid-based medicines for neurological disorders-Clinical evidence. Molecular Neurobiology, 36, 129-136. https://doi.org/10.1007/s12035-007-0003-4</Citation></Reference><Reference><Citation>Xue, Y. C., Ng, C. S., Xiang, P., Liu, H., Zhang, K., Mohamud, Y., &amp; Luo, H. (2020). Dysregulation of RNA-binding proteins in amyotrophic lateral sclerosis. Frontiers in Molecular Neuroscience, 13, 78. https://doi.org/10.3389/fnmol.2020.00078</Citation></Reference><Reference><Citation>Yiangou, Y., Facer, P., Durrenberger, P., Chessell, I. P., Naylor, A., Bountra, C., Banati, R. R., &amp; Anand, P. (2006). COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurology, 6, 12. https://doi.org/10.1186/1471-2377-6-12</Citation></Reference><Reference><Citation>Zhao, P., Ignacio, S., Beattie, E. C., &amp; Abood, M. E. (2008). Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: Implications for excitotoxicity. The European Journal of Neuroscience, 27, 572-579. https://doi.org/10.1111/j.1460-9568.2008.06041.x</Citation></Reference><Reference><Citation>Zou, S., &amp; Kumar, U. (2018). Cannabinoid receptors and the endocannabinoid system: Signaling and function in the central nervous system. International Journal of Molecular Sciences, 19, 833.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>